Get the Stockscreener App
0.7505
2.70%
-0.0208
After Hours:
.74
-0.0105
-1.40%
Akari Therapeutics Plc Adr stock is traded at $0.7505, with a volume of 79,211.
It is down -2.70% in the last 24 hours and down -26.49% over the past month.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
See More
Previous Close:
$0.7713
Open:
$0.787
24h Volume:
79,211
Relative Volume:
0.40
Market Cap:
$24.48M
Revenue:
-
Net Income/Loss:
$-12.29M
P/E Ratio:
-0.7217
EPS:
-1.0399
Net Cash Flow:
$-9.07M
1W Performance:
+1.46%
1M Performance:
-26.49%
6M Performance:
-45.22%
1Y Performance:
-69.98%
1-Day Range:
$0.7411
$0.80
1-Week Range:
$0.72
$0.83
52-Week Range:
$0.5714
$3.15
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(646) 350-0702
Address
22 BOSTON WHARF ROAD, BOSTON
Compare AKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.7505 | 25.16M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.21 | 108.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.91 | 69.37B | 14.25B | 4.58B | 3.56B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.59 | 62.38B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
821.97 | 51.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.95 | 34.94B | 398.11M | -1.03B | -868.57M | -5.7032 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Initiated | Maxim Group | Buy |
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com India
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com Philippines
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com
Form 424B5 Akari Therapeutics Plc - StreetInsider
Akari Therapeutics stock falls after $2.5 million registered offering - Investing.com
Akari Therapeutics secures $2.5 million through registered offering - Investing.com India
$2.5M raise: Akari Therapeutics to issue 3,125,000 ADSs in registered direct offering - Stock Titan
Akari Therapeutics files new patents for cancer treatment technology - Investing.com India
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 - Sahm
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Can momentum traders help lift Tripadvisor Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Analyzing PRA Group Inc. with risk reward ratio chartsJuly 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
Institutional scanner results for ANSYS Inc.Entry Point & Verified Technical Trade Signals - newser.com
Does SRTY fit your quant trading modelPortfolio Gains Report & Stock Timing and Entry Methods - newser.com
Akari Therapeutics files patent for novel cancer treatment approach By Investing.com - Investing.com South Africa
Akari Therapeutics files patent for novel cancer treatment approach - Investing.com
Revolutionary Spliceosome Cancer Treatment: Akari Files Patent for First-in-Class ADC Platform Technology - Stock Titan
Is BSIIU stock reversal real or fake2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Security Solutions Inc.2025 Market Outlook & Smart Money Movement Tracker - newser.com
Applying big data sentiment scoring on HLITJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Novel ADC Developer Akari Therapeutics to Showcase Pipeline at Major Healthcare Conference - Stock Titan
Next-Gen Cancer Drug Developer Akari Therapeutics Showcases Novel IO-Payload ADC Platform - Stock Titan
Advanced analytics toolkit walkthrough for Educational Development CorporationShare Buyback & Free Expert Approved Momentum Trade Ideas - Newser
What high frequency data says about MGTXOil Prices & Free Technical Confirmation Trade Alerts - Newser
Using AI based signals to follow BWXT2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Analyzing recovery setups for Guardian Pharmacy Services Inc. investorsMarket Volume Report & Weekly High Return Stock Forecasts - Newser
Akari Therapeutics completes $2.8 million note offering and extends warrant terms - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Cancer Drug Developer Akari Therapeutics Showcases Pipeline at Webull Biotech Conference - Stock Titan
Is BACQR still worth holding after the dipEquity Market Return Forecast Model Update - Newser
Insider Stock Buying Reaches US$1.79m On Akari Therapeutics - Sahm
Akari Therapeutics Reveals Breakthrough Progress in Cancer-Fighting Drug Development - Stock Titan
Akari Therapeutics advances cancer-fighting ADC technology with PH1 payload - Investing.com India
Revolutionary Cancer Drug PH1 Targets KRAS, BRAF While Activating Immune System Against Tumors - Stock Titan
Akari Therapeutics CEO Shares Exclusive Insights on Next-Gen Cancer Drug Development Strategy - Stock Titan
INKT Stock Quote Price and Forecast - CNN
Akari Therapeutics shareholders approve equity plan increase and director elections - Investing.com
Akari Therapeutics Expands Global IP Portfolio: Key Patent Win for Cancer Drug Platform in India - Stock Titan
AKTX CEO buys 10,000 ADS at $1.20 in Form 4 insider filing - Stock Titan
Akari Therapeutics secures Indian patent for cancer drug payload - Investing.com India
Akari's Revolutionary Cancer Drug Technology Wins Key Patent in India's 2.08M Patient Market - Stock Titan
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology - Sahm
Akari Therapeutics CEO Reveals Latest Oncology ADC Developments at Major Webull Investor Event - Stock Titan
Akari Therapeutics Reports Q1 2025 Financial Results - TipRanks
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):